Faster TRD Remission: What Dose Optimization Means

The News: Clinicians Are Being Urged to Move Faster on TRD

A new analysis published in Psychiatric Times (April 2026) makes a pointed case: patients with treatment-resistant depression (TRD) are spending too long at subtherapeutic doses, tolerating unaddressed side effects, and waiting too many weeks between meaningful medication adjustments. The article argues that structured symptom measurement tools, more proactive dose escalation, and better side-effect management can meaningfully shorten the path to remission.

While the piece addresses the broader TRD landscape — including antidepressants, augmentation strategies, and newer interventions — its core logic applies directly and urgently to oral ketamine therapy, one of the fastest-growing tools in the TRD toolkit.

Why This Matters Specifically for Oral Ketamine Tablets

Oral ketamine presents a unique dosing challenge that makes the Psychiatric Times guidance especially relevant. Unlike IV infusions — where dosing is controlled to the milligram in a clinical setting — tablets and troches depend on highly variable patient factors: stomach contents, GI transit speed, first-pass liver metabolism, and individual cytochrome P450 enzyme activity. Two patients taking the same 150 mg tablet can absorb meaningfully different amounts of active ketamine.

This variability makes structured, frequent symptom tracking not just helpful but essential. If a prescriber waits four to six weeks between check-ins (a common rhythm borrowed from traditional antidepressant protocols), a patient on oral ketamine may have been under-dosed the entire time — or may have been experiencing manageable side effects that quietly eroded adherence. The Psychiatric Times framework pushes back against that wait-and-see culture.

Dose Adjustment: What 'Moving Fast' Looks Like in Practice

For oral ketamine patients, dose optimization typically involves titrating upward in 25–50 mg increments based on response and tolerability, often over a 2–4 week window. The new guidance reinforces that clinicians shouldn't let patients linger at a starting dose if validated symptom scales — PHQ-9, MADRS, or similar — show insufficient early movement.

This is one area where oral tablets have a practical advantage over infusions: adjustments can often be made remotely, without requiring the patient to travel to a clinic. A prescriber can update a tablet dose between appointments if symptom data supports it, compressing the optimization timeline considerably. Troches offer similar flexibility, though tablet formulations with defined release profiles may offer more predictable absorption curves for dose-response tracking.

Oral vs. Infusion: The Access and Titration Trade-Off

IV ketamine infusions remain the gold standard for acute TRD response — onset can be dramatic and measurable within hours or days. But the Psychiatric Times piece implicitly highlights a structural problem with infusion-based care: the logistics of clinic scheduling slow down the titration cycle. When dose adjustments require a new appointment, a patient can lose weeks.

Oral ketamine tablets occupy a different position in this trade-off. Response is slower and less predictable per dose, but the ability to adjust at home — paired with regular telehealth check-ins and digital symptom tracking — allows for a more nimble optimization process over the medium term. For patients with limited clinic access, this flexibility may translate into faster real-world remission, even if the per-session pharmacokinetics are less potent.

Sublingual troches offer a middle ground: faster absorption than swallowed tablets (bypassing significant first-pass metabolism), but still home-administered. The trade-off is that troche dosing is harder to standardize across compounding pharmacies, making symptom-data-driven titration somewhat less precise.

The Role of Side-Effect Management in Staying on Track

The Psychiatric Times analysis places significant weight on proactively addressing side effects as a prerequisite for reaching remission — the logic being that patients who discontinue treatment early due to tolerability problems never have the chance to respond. For oral ketamine, the most commonly reported issues are dissociation, nausea, dizziness, and cognitive fogginess. These tend to be dose-dependent and transient, but if left unaddressed, they become reasons patients quietly stop taking their medication.

Clinicians following the new guidance would screen for these symptoms at every touchpoint and intervene early — adjusting dosing schedules, recommending administration with a light meal to blunt absorption peaks, or timing doses to coincide with evenings when dissociative effects are less disruptive. For tablet patients, this kind of practical coaching is often the difference between a 60-day trial that works and one that quietly fails.

Practical Steps: Getting More From Your Treatment

Based on the clinical principles highlighted in the Psychiatric Times analysis, here are concrete things oral ketamine tablet patients can do right now:

• Track symptoms weekly. Use a standardized tool like the PHQ-9 or a clinician-provided scale. Bring the scores to every appointment.
• Report side effects early and specifically. Vague discomfort is hard to act on; specific descriptions (duration, intensity, timing relative to the dose) help prescribers intervene precisely.
• Ask about dose review timelines. If your prescriber is planning to reassess in six weeks, ask whether two to three weeks of symptom data could support an earlier adjustment.
• Understand your absorption variables. Taking tablets on a completely empty stomach versus a light meal can shift peak plasma levels meaningfully — discuss consistency of administration with your provider.
• Don't stop quietly. If side effects are making you want to discontinue, contact your prescriber first. Many tolerability issues have straightforward solutions that don't require stopping treatment.

The broader message from this clinical guidance is one the oral ketamine community should internalize: reaching remission is an active, data-driven process — not a passive waiting game.